Get the Stockscreener App
6.75
2.74%
0.18
After Hours:
6.84
0.09
+1.33%
Organon Co stock is traded at $6.75, with a volume of 8.05M.
It is up +2.74% in the last 24 hours and down -36.80% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$6.57
Open:
$6.61
24h Volume:
8.05M
Relative Volume:
1.61
Market Cap:
$1.75B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.5072
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-26.31%
1M Performance:
-36.80%
6M Performance:
-47.80%
1Y Performance:
-64.06%
1-Day Range:
$6.55
$6.925
1-Week Range:
$6.18
$7.64
52-Week Range:
$6.18
$18.94
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.75 | 1.71B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
862.86 | 757.06B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
188.87 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
218.04 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.79 | 235.26B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.98 | 215.51B | 63.99B | 19.05B | 14.72B | 7.5596 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon & Co. $OGN Holdings Cut by Fisher Funds Management LTD - MarketBeat
Organon & Co. Stock Plummets to New 52-Week Low of $6.18 - Markets Mojo
Co. (7XP) stock survive global slowdownQuarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN) - MSN
KLCM Advisors Inc. Decreases Stake in Organon & Co. $OGN - MarketBeat
Crisis at Organon: Leadership Ousted Amid Sales Scandal - AD HOC NEWS
Tangible book value per share of Organon & Co. – BMV:OGN - TradingView
Organon & Co. (OGN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
OGN 8-K/A discloses interim Executive Chair compensation terms - Stock Titan
The Vanguard Group files 13G/A for Organon with 13.82% stake - Stock Titan
Organon & Co. Common Stock (NY: OGN - FinancialContent
The Escalator: Organon, Kenvue, Real Chemistry and more - Medical Marketing and Media
Organon & Co. $OGN Shares Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Co. (7XP) stock in 20252025 Sector Review & Safe Entry Point Alerts - newser.com
Organon & Co. (OGN) Stock forecasts - Yahoo! Finance UK
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon (OGN) Price Target Decreased by 15.36% to 11.05 - Nasdaq
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat
Organon Looks For New CEO Amid Investigation Into Front-Loading Contraceptive Implant Sales - Citeline News & Insights
Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st
Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat
D.A. Davidson & CO. Sells 50,248 Shares of Organon & Co. $OGN - MarketBeat
Why Organon (OGN) Stock Is Down Today - Yahoo Finance
Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade
Organon hit hard over ousted CEO scandal - The Pharma Letter
The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Hits New 52-Week Low After Analyst Downgrade - MarketBeat
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - FinancialContent
Organon & Co. (NYSE:OGN) Downgraded by Piper Sandler to Underweight - MarketBeat
Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛
Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize
Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia
Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ
Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada
Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire
Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma
Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - Barron's
Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ
Organon CEO exits after internal probe over ‘channel stuffing’ to boost sales - Endpoints News
Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance
Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's
Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener
Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):